Vortioxetine

Vortioxetine

Systematic (IUPAC) name
1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine
Clinical data
Pregnancy cat.	?
Legal status	Investigational
Identifiers
CAS number	508233-74-7 Y
ATC code	None
ChemSpider	26286009 Y
Synonyms	Lu AA21004; Lu-AA-21004
Chemical data
Formula	C18H22N2S
Mol. mass	298.45 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C19H23NS/c1-14-7-8-18(15(2)13-14)21-19-6-4-3-5-17(19)16-9-11-20-12-10-16/h3-8,13,16,20H,9-12H2,1-2H3 Y Key:CDJKHWPNYGAMAT-UHFFFAOYSA-N Y
Y(what is this?)  (verify)

Vortioxetine (Lu AA21004) is an experimental drug currently under development by Lundbeck and Takeda for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD). It is a so-called "serotonin modulator and stimulator", and acts as a serotonin transporter blocker (K_i = 1.6 nM), 5-HT_1A receptor near-full agonist (K_i = 15 nM; IA = 80%), 5-HT_1B receptor partial agonist (K_i = 33 nM), 5-HT_3A receptor antagonist (K_i = 3.7 nM), and 5-HT₇ receptor antagonist (K_i = 19 nM). It also has affinity for the β₁-adrenergic receptor (K_i = 46 nM), though its intrinsic activity at this site is not yet known. In 2009, vortioxetine began phase III clinical trials. In a double-blind, randomized, placebo-controlled clinical trial with venlafaxine as an active reference, it was found to be efficacious in treating MDD, while having fewer side effects than its comparator. A New Drug Application (NDA) is not expected to be submitted to the Food and Drug Administration (FDA) until 2012.

See also

• Tedatioxetine